Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE
Our results demonstrate that the addition of ruxolitinib to UCB-Tregs increases UCB-Tregs suppressor function and their persistence <i>in vivo</i>, downregulates systemic inflammation, and controls cutaneous SLE but does not add to UCB-Treg-mediated improvement in renal manifestations.
Authors
- Ximing Tang (ORCID: https://orcid.org/0000-0001-6534-6852)
- Simrit Parmar (ORCID: https://orcid.org/0000-0003-1798-9233)
- Maria Gabriela Raso (ORCID: https://orcid.org/0000-0003-2105-5556)
- Christopher R. Flowers (ORCID: https://orcid.org/0000-0002-9524-3990)
- Meixian Huang (ORCID: https://orcid.org/0000-0002-6245-9365)
- Mi-Ae Lyu
- Ke Zeng (ORCID: https://orcid.org/0009-0009-1357-0444)
- Tara Sadeghi
Institutions
- The University of Texas MD Anderson Cancer Center (US)
- Texas A&M University (US)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-02-05
- DOI
- https://doi.org/10.3389/fimmu.2025.1449693
- Citations
- 1
- Primary Topic
- T-cell and B-cell Immunology
- Type
- article
- Field-Weighted Citation Impact
- 0.80